Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to reduce ...

Novo bets on 'triple G' obesity drug in up to $2 billion deal with Chinese biotech Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so ...

Under the terms of the agreement, Kyorin will receive $55m upfront and will be eligible for milestone payments of up to ...

A digital therapeutics start-up which uses augmented reality (AR) glasses to aid people suffering from disorders including Parkinson's disease and multiple sclerosis will this week announce a £ ...

About Checkpoint Therapeutics, Inc. Checkpoint is a commercial-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments ...

1 GKE cluster on GCP 1 Kops on GCE cluster Istio (Dual control plane, single mesh) Anthos Config Management (both clusters configured for the same config repo) GKE Connect installed on both clusters ...

A high throughput screen of >30,000 diverse repressor domains from across the tree of life identifies repressor domains with unique structures that underpin enhanced epigenetic effector domain ...

Swiss pharma giant Novartis came out on top last month in the mergers and acquisitions (M&As) space with its buyout of Massachusetts-based Anthos Therapeutics. The deal is worth up to $2.15 billion in ...

Recently, Novartis AG (NYSE:NVS) announced a deal to repurchase Anthos Therapeutics for up to $3.1 billion. This acquisition allows the company to regain control over Abelacimab, a promising drug ...

Last month, Novartis announced that it will acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company. The acquisition will add abelacimab ...